Maintenance therapy in hormone receptor-positive and human epidermal growth factor receptor 2-positive metastatic breast cancer: a real-world multicenter retrospective study.

ABSTRACT:

Introduction

The optimal choice of maintenance therapy after standard first-line treatment for hormone receptor (HR)-and human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) remains uncertain. Therefore, we evaluated the clinical value of trastuzumab combined with endocrine therapy (ET group) compared with trastuzumab combined with chemotherapy (CT group) as maintenance therapy in patients with HR+/HER2+ MBC.

Methods

The clinical data of 117 patients with HR+/HER2+ MBC who received trastuzumab combined with endocrine therapy or chemotherapy as maintenance therapy at three hospitals in China between January 2012 and October 2022 were retrospectively analyzed. The primary endpoint was progression-free survival (PFS). To construct a nomogram,

SUBMITTER: Bao S 

PROVIDER: S-EPMC12827085 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature